# AlphaBet (NCT05383079)

> Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: lutetium-177 PSMA-I&T plus radium-223
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05383079
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Metastatic Castration-resistant Prostate Cancer; MCRPC; Prostate Cancer
- Interventions: Lutetium-177 PSMA-I&T; Radium-223
- Enrollment: 36
- Primary outcome: Dose Limiting toxicities (DLTs)
- Primary outcome: Maximum Tolerated dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D)
- Primary outcome: 50% Prostate-Specific Antigen Response Rate (PSA-RR)

## Indexed commentary on AlphaBet so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 7 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=alphabet-nct05383079

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05383079", "email": "<work email>"}; the inbox owner confirms by the emailed link.
